The balance between collagen synthesis and degradation in diffuse lung disease

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 18, Issue 1, 2001, Pages 27-33

  Thickett, D R ^a   Poole, A R ^a   Millar, A B ^a  

^a NONE   (United Kingdom)

Author keywords

Collagen production; Collagen turnover; Interstitial lung disease; Pathogenesis; Pulmonary fibrosis

Indexed keywords

COLLAGEN; COLLAGENASE; GAMMA INTERFERON; PIRFENIDONE;

COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; ENZYME INHIBITION; ENZYME SYNTHESIS; GAS EXCHANGE; HUMAN; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; COLLAGEN; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERFERON TYPE II; LUNG DISEASES, INTERSTITIAL; PULMONARY FIBROSIS; PYRIDONES;

EID: 0035068787     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Collagen polymorphism in the lung: An immunohistochemical study of pulmonary fibrosis
2. What holds us together? Why do some of us fall apart? What can we do about it?
3. Matrix metalloproteinases: Matrix degradation and more
4. Collagenases
5. Matrix metalloproteinases 2,9,13 and tissue inhibitors of metalloproteinases 1 and 2 in experimental silicosis
6. Matrix metalloproteinases: A review
7. Tissue inhibitors of metalloproteinases structure, regulation and biological function
8. Cytokines and pulmonary fibrosis
9. The molecular basis of asbestos induced lung injury
10. Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosis
11. Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome
12. Protein metabolism during bleomycin-induced pulmonary fibrosis in rabbits. In vivo evidence for collagen accumulation because of increased synthesis and decreased degradation of newly synthesised collagen
13. Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis
14. Increased type 1 procollagen mRNA transcripts in the lungs of mice during the development of bleomycin-induced fibrosis
15. Enhanced type III collagen gene expression during bleomycin-induced lung fibrosis
16. Collagen synthesis and degradation during the development of asbestos-induced pulmonary fibrosis
17. Type III and type I procollagen markers in fibrosing alveolitis
18. Propeptide levels of type III and type I procollagen in the serum and bronchoalveolar lavage fluid of patients with pulmonary sarcoidosis
19. Changes in collagen turnover in early acute respiratory distress syndrome
20. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment
21. Quantitation of types I and III collagen in biopsy lung samples from patients with cryptogenic fibrosing alveolitis
22. Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis
23. Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis
24. Early detection of type III procollagen peptide in acute lung injury. Pathogenetic and prognostic significance
25. Determination of serum concentrations of type III procollagen peptide in mechanically ventilated patients
26. Type III procollagen peptide in bronchoalveolar lavage fluid poor indicator of course and prognosis in sarcoidosis
27. Fibronectin and procollagen III levels in the bronchoalveolar lavage of asbestos exposed human subjects and sheep
28. Evaluation of serum aminoterminal propeptide of type II procollagen as an early marker of active fibrotic process in asbestos-exposed workers
29. Hyaluronate and type III procollagen peptide in BALF as markers of disease activity in Farmer's lung
30. Serum and urine analysis of the amino-terminal procollagen peptide type III by radioimmunoassay with antibody Fab fragments
31. Immunoelectron microscopic localisation of laminin. Type IV collagen and type III pN-collagen in reticular fibres of human lymph nodes
32. Simultaneous measurement of collagen type VI related antigen and procollagen type III N propeptide levels in bronchoalveolar fluid
33. Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis
34. Collagenase and fibronectin in bronchoalveolar lavage fluid in patients with sarcoidosis
35. Comparison between lung parenchyma and bronchoalveolar lavage collagenolytic activity
36. Production of collagenase and tissue inhibitor of metalloproteinases by fibroblasts derived from normal and fibrotic human lungs
37. Lung collagenase inhibitors and spontaneous and latent collagenase activity in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis
38. Higher concentrations of matrix-metalloproteinases in bronchoalveolar lavage fluid of patients with ARDS
39. Increased expression of MMP in lung tissue of patients with interstitial lung diseases
40. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-I) down-regulation on cultured human synovial fibroblasts
41. Pirfenidone: A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production
42. Inhibition of tumour necrosis factor and subsequent endotoxin shock by pirfenidone
43. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model
44. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone
45. A preliminary study of long term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis
46. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin mouse model of lung fibrosis: Downregulation of TGF beta and procollagen I and III gene expression
47. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway